Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

April 30, 2013


Risk-based Approach to Monitoring:
Deployment Insights and Lessons Learned

Speakers for this Event:
  • Dan White, Vice President, Global Operations, Quintiles   Learn More
  • Amanda Sax, Senior Director, Integrated Processes and Technologies, Quintiles   Learn More
  • Bringing a therapy to market can cost billions. Now with support from the FDA and EMA, the industry is ready to realize the promise of risk-based monitoring. Quintiles has been using elements of RBM since 2001 as a smarter, more efficient approach to clinical trial execution that focuses on critical data. In this webinar, Quintiles will share recent research insights and real experiences using a modernized approach to risk-based monitoring.

    By integrating best practices from RBM studies with new approaches and innovative technology, we will share common challenges, lessons learned, and how to best apply processes and technology to deliver the optimal outcome for a study. Specifically, we will explore how to:

    • Apply risk analysis to each study to evaluate the scientific and operational risk of each protocol
    • Identify the optimal monitoring approach for each study
    • Integrate dynamic monitoring and data analysis for faster identification of patient and study issues
    • Place resources for optimal execution
    • Leverage on-demand insights to implement risk-based processes and workflows compatible with a global regulatory requirements
    THIS PROGRAM IS INTENDED FOR

    EVPs, VPs, Directors, Heads, Managers, Principal Scientists of:

    • Clinical R&D
    • Clinical Operations (Clinical Project Leads, Clinical Program Managers, Therapeutic Heads, Clinical Data Managers, Pharmacovigilance Scientist)
    • Regulatory Affairs
    • Medical Affairs
    • Outsourcing Management
    ABOUT OUR SPEAKERS

    Dan White, Vice President, Global Operations, Quintiles

    Dan White is Vice President of Global Operations for Quintiles centralized monitoring group (PCC) as well as the endpoint adjudication group (CEVA). In this position, Dan leads over 26 PCC locations around the world including centers in Latin America, Eastern/Western Europe, Australia, South Africa, India, and the US (largest center). Dan is Quintiles subject matter expert on risk-based monitoring, working with sponsors on the implementation of risk-based monitoring across Quintiles organization. Dan has been with Quintiles over 13 years and is based in NC out of the RTP office.

    Amanda Sax, Senior Director, Integrated Processes and Technologies, Quintiles

    Amanda leads the development of Quintiles’ approach to Risk-Based Monitoring, Data-driven Trial Execution, which optimizes the clinical execution strategy for each study to help customers manage risk and improve efficiency. In this role, she oversees the processes that direct Quintiles Infosario®, a technology solution that seamlessly integrates data and systems to provide transparency and collaboration and drives faster, better-informed decisions.

    OUR XTALKS PARTNER FOR THIS EVENT

    Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, and consulting solutions worldwide. The Quintiles network of more than 27,000 engaged professionals in 59 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

     
    Copyright © 2016-2017 Honeycomb Worldwide Inc.